COVID-19 – [illegible]

[illegible]

[illegible]

2019[illegible]Synowiec et al., 2021[illegible]2[illegible]SARS-CoV-2[illegible]1A[illegible]1B[illegible]



[illegible][illegible]-SARS-CoV-2 [illegible]COVID-19[illegible] [illegible] [illegible]A: cat. no. HS-452 011, 1:1000; B: cat. no. HS-452 111, 1:500[illegible]COVID-19[illegible]Ventana Benchmark XT[illegible]: 100µm[illegible]

[illegible]Dres. Krasemann/Heinrich/Pfefferle[illegible]UKE-[illegible]/[illegible]

SARS-CoV-2[illegible]RNA[illegible]:[illegible]Synowiec et al., 2021[illegible]2[illegible]

SARS - Virus



[illegible]2[illegible]SARS-CoV-2[illegible] [illegible] Pizzato et al., 2022[illegible]RNA[illegible]

[illegible]/[illegible]Magazine et al., 2022[illegible]WHO[illegible]Sars-CoV-2[illegible]VOCs[illegible]α[illegible]β[illegible]γ[illegible]δ[illegible]omicron[illegible]Magazine et al., 2022[illegible]RNA[illegible]α[illegible]omicron[illegible]R203K+G204R[illegible]SARS-CoV-2[illegible]Johnson et al., 2022[illegible]

SARS-CoV-2[illegible]

[illegible]COVID-19[illegible](Krasemann et al., 2022[illegible]HistoSure[illegible]SARS-CoV-2[illegible]3 [illegible]Nsp3[illegible]RNA[illegible]HistoSure[illegible]SARS-CoV-2[illegible]SARS-CoV-2[illegible]omicron [illegible]Krasemann et al., 2022[illegible]

[illegible]Sars-CoV-2[illegible]SARS-CoV-2[illegible]ACE2 [illegible]2[illegible]TMPRSS2[illegible]Gupta et al., 2020[illegible]ACE2[illegible]Ambrocio-Ortiz et al., 2021[illegible]ACE2[illegible]COVID-19[illegible]Gheware et al., 2022[illegible]

[illegible]ACE2[illegible]K18-hACE2[illegible]SARS-CoV[illegible]McCray Jr. et al., 2006[illegible]3[illegible]SARS-CoV-2 RNA[illegible]SARS-CoV-2[illegible]Abassi et al., 2023[illegible]



3CoV-1/2HS-452 111MAC2DAPI
SARS-CoV-2 δLeila Abassi, Marina Greweling-Pils & Luka Čičin-Šain

COVID-19

COVID-19COVID-19Vanderheiden and Klein, 2022“”Theoharides and Kempuraj, 2023

ACE2Vanderheiden and Klein, 2022TMPRSS2neuropilin-1 NRP1SARS-CoV-2Davies et al., 2020

Sars-CoVK18-hACE245





⊠4⊠ ⊠⊠⊠⊠⊠⊠-SARS-Cov-2⊠⊠⊠⊠⊠⊠⊠#4A8 ⊠cat. no. HS-452 011, ⊠⊠⊠⊠ 1:1000; ⊠⊠⊠⊠⊠⊠PFA ⊠⊠⊠B⊠⊠⊠SARS-CoV-2⊠K18-hACE2⊠⊠⊠⊠⊠⊠A⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠ ⊠⊠⊠⊠⊠⊠⊠⊠⊠DAPI⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠Čičin-Šain⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠5⊠ ⊠⊠⊠-Sars-Cov-2 ⊠⊠⊠⊠⊠⊠⊠#53E2 ⊠cat. no. HS-452 111, ⊠⊠⊠⊠ 1:1000; DAB⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠B⊠⊠⊠SARS-CoV-2⊠A⊠⊠⊠⊠⊠⊠⊠⊠K18-hACE2⊠⊠⊠⊠⊠⊠⊠⊠ ⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠Čičin-Šain⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

SARS-CoV-2⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠6⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠7⊠⊠





☒ 6☒☒☒☒☒- CD11b ☒cat. no. HS-384 117, ☒☒☒☒ 1:200, DAB☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒A☒☒☒☒☒☒PBS☒☒☒☒☒B☒K18-hACE2☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒

☒☒☒☒☒☒☒☒☒☒☒☒☒Čičin-Šain☒☒☒Kröger☒☒☒☒☒☒☒☒☒☒

☒ 7☒☒☒☒☒-Chil3 ☒cat. no. HS-442 017, ☒☒☒☒ 1:200, DAB☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒A☒☒☒☒☒☒PBS☒☒☒☒☒B☒K18-hACE2☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒

☒☒☒☒☒☒☒☒☒☒☒☒☒Čičin-Šain☒☒☒Kröger☒☒☒☒☒☒☒☒☒☒

☒☒COVID-19☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒Matschke et al., 2022☒☒☒Theoharides and Kempuraj, 2023; Radke et al., 2024☒☒

☒☒☒☒☒“☒☒-☒☒☒☒”☒☒☒ Theoharides and Kempuraj, 2023☒☒

☒☒

Cat. No.	Product Description	Application	Quantity	Price	Cart
HS-452 111	Nucleocapsid CoV-1/2, mouse, IgG	WB ICC IHC IHC-P (FFPE)	200 µl	US$420.00	
HS-452 111BT	Nucleocapsid CoV-1/2, mouse, IgG, biotin	IHC-P (FFPE) ELISA	100 µg	US$470.00	
HS-452 011	Nucleocapsid CoV-2, mouse, IgG	WB ICC IHC IHC-P (FFPE) ELISA	200 µl	US$420.00	
HS-452 011BT	Nucleocapsid CoV-2, mouse, IgG, biotin	IHC-P (FFPE)	100 µg	US$470.00	

Result count: **4**

☒☒☒Christel Bonnas☒☒
HistoSure☒☒☒☒☒
Christel☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒HistoSure☒☒☒☒☒☒☒☒☒☒☒☒
☒☒☒☒☒☒☒☒☒☒

Abassi et al., 2023. Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. PMID: 38005829

Ambrocio-Ortiz et al., 2021. Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. PMID: 34451902

Davies et al., 2020. Neuropilin 1 as a new potential SARS CoV 2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID 19. PMID: 33000221

Gheware et al., 2022. ACE2 protein expression in lung tissues of severe COVID-19 infection. PMID: 35260724

Gupta et al. 2020. Extrapulmonary manifestations of COVID-19. PMID: 32651579

Johnson et al., 2022. Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. PMID: 34671771

Krasemann et al., 2022. Assessing and improving the validity of COVID-19 autopsy studies - a multicenter approach to establish essential standards for immunohistochemical and ultrastructural analyses. PMID: 35930888

Magazine et al., 2022. Mutations and Evolution of the SARS-CoV-2 Spike Protein. PMID: 35337047

Matschke et al., 2022. Young COVID-19 Patients Show a Higher Degree of Microglial Activation When Compared to Controls. PMID: 35785352

McCray PB Jr. et al., 2006. Lethal infection in K18-hACE2 mice infected with SARS-CoV. PMID: 17079315

Pizzato et al., 2022. SARS-CoV-2 and the Host Cell: A Tale of Interactions. https://doi.org/10.3389/fviro.2021.815388

Synowiec et al., 2021. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. PMID: 33441314

Theoharides and Kempuraj, 2023. Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. PMID: 36899824

Radke et al., 2024. Proteomic and transcriptomic profiling of brainstem, cerebellum and olfactory tissues in early- and late-phase COVID-19. PMID: 38366144

Vanderheiden and Klein 2022. Neuroinflammation and COVID-19. PMID: 35863101